Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women

Labrie, Fernand; Archer, David F.; Bouchard, Céline; Fortier, Michel; Cusan, Lionel; Gomez, José‐Luis; Girard, Ginette; Baron, Mira; Ayotte, Normand; Moreau, M.; Dubé, Robert; Côté, Isabelle; Labrie, Claude; Lavoie, Lyne; Berger, Louise; Gilbert, Lucy; Martel, Céline; Balser, John

doi:10.1097/gme.0b013e31819e85c6

Cited by 177 publications

(98 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent reports support the use of androgens and testosterone in women with vaginal atrophy and research is ongoing into the effectiveness of pilocarpine, a nonselective muscarinic receptor agonist [32][33][34][35][36]. A recently completed trial of intravaginal dehydroepiandrosterone (Prasterone) showed an effect on vaginal atrophy without elevation of estradiol or testosterone above usual postmenopausal levels [37].…”

Section: Discussionmentioning

confidence: 99%

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

et al. 2011

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate early data regarding the impact of daily vaginal testosterone on estradiol and testosterone levels in breast cancer patients receiving treatment with aromatase inhibitors.2. Explain the potential clinical benefits of vaginal testosterone therapy to treat vaginal atrophy in women with breast cancer receiving long-term aromatase inhibitor therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. ABSTRACT Breast CancerThe

show abstract

Section: Discussionmentioning

confidence: 99%

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…41 Despite not having any systemic steroid effects, intravaginal DHEA improved various parameters of sexual function, including domains, such as sexual desire. 42 However, longer-term studies are needed to confirm these data.…”

Section: Androgens and Dehydroepiandrosteronementioning

confidence: 87%

Management of Postmenopausal Vaginal Atrophy: Review of Literature

Dayal¹,

Yadav²

2017

Journal of SAFOMS

View full text Add to dashboard Cite

Aim: As there is dilemma for treatment of postmenopausal vaginal atrophy, effort has been made to review the literature for the same.Background: About half of all postmenopausal women will experience symptoms related to urogenital atrophy. Vaginal atrophy becomes clinically apparent 4 to 5 years after menopause, and subjective complaints as well as objective changes are present in 25 to 50% of all postmenopausal women.

show abstract

“…W badaniach Labrie'ego i wsp. u kobiet, którym podawano DHEA dopochwowo, odnotowano korzystny wpływ terapii na libido, wyrażający się poprawą w 4 aspektach życia seksualnego: przeżywaniu orgazmu, pożądaniu, pobudzeniu i obecności dyspareunii [11]. Podobnych wyników nie uzyskano podczas doustnego podawania preparatów z DHEA [4].…”

Section: Dehydroepiandrosteron W Miejscowej Terapii Kobiet Z Objawamiunclassified

New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy

Gałczyński¹,

Poleszak²,

Kasperek³

et al. 2013

View full text Add to dashboard Cite

111 StreszczenieWedług jednej z nowszych teorii objawy menopauzalne nie wynikają jedynie ze spowodowanego wygaś-nięciem funkcji jajników niedoboru estrogenów, ale są także związane ze stopniowym, postępującym przez kilka lat zmniejszeniem stężenia dehydroepiandrosteronu (DHEA) wydzielanego przez nadnercza. Ponad 50% kobiet po menopauzie zgłasza objawy związane z atrofią nabłonka pochwy: podrażnienie, nawracające infekcje, uczucie suchości, ból podczas współżycia. Ogólnoustrojowa terapia hormonalna z użyciem samych estrogenów lub w połączeniu z progestagenami skutecznie przeciwdziała tym objawom, jednak wiąże się z możliwością wystąpienia działań niepożądanych. Poza tym u kobiet, u których jedynymi uciążliwymi objawami są te zwią-zane z atrofią pochwy, warto pomyśleć o terapii miejscowej. Do obiecujących wyników badań należą te nad dopochwowym zastosowaniem DHEA, w których założono, że terapia fizjologicznymi dawkami DHEA przyczyni się do zwiększenia stężenia androgenów i estrogenów syntetyzowanych miejscowo w tkance poprzez mechanizmy intrakrynne przy niewielkim działaniu ogólnoustrojowym. W grupie kobiet leczonych DHEA podawanym dopochwowo wykazano zmniejszenie objawów atrofii pochwy, regresję zmian dysplastycznych na szyjce macicy oraz zwiększenie libido.Słowa kluczowe: dehydroepiandrosteron, atrofia urogenitalna, menopauza. SummaryAccording to novel theory menopausal symptoms are not only connected with estrogen deficiency due to diminished ovarian estrogen secretion, but are also associated with the gradual, progressive decline in the level of dehydroepiandrosterone (DHEA) secreted by the adrenal glands. Over 50% of postmenopausal women report symptoms associated with urogenital atrophy, ie: irritation, recurrent infections, dryness, dyspareunia. Systemic hormonal therapy with estrogens or in combination with progestins is an effective treatment of these symptoms, however, it is associated with some adverse effects. In addition, it is worthwhile to think about local therapy in case of women who have only symptoms associated with urogenital atrophy. Promising are results of the studies of DHEA intravaginal therapy, in which it was assumed that physiological doses of DHEA contribute to an increase in androgens and estrogens synthesized locally in tissues by intracrine mechanisms with low systemic effects. Previous studies have shown that intravaginal DHEA application reduce the symptoms of vaginal atrophy, regress low-grade cervical dysplasia and increase libido.

show abstract

Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women

Cited by 177 publications

References 65 publications

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

Management of Postmenopausal Vaginal Atrophy: Review of Literature

New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy

Contact Info

Product

Resources

About